Kinoshita M, Kusukawa R, Shimono Y, Motomura M, Tomonaga G, Hoshino T
Jpn Circ J. 1978 May;42(5):553-60. doi: 10.1253/jcj.42.553.
Dilitazem hydrochrolide, a potent coronary dilator, was administered in 18 patients to evaluate its effect on renal hemodynamics and urinary electrolyte excretion. Renal blood flow (RBF), glomerular filtration rate (GFR), and cardiac output were determined in 8 ambulatory patients by means of external counting of radioisotope dilution before and 3 or 4 weeks after the medication. Althoug RBF tended to increase after the therapy, there was no statistically significant change in RBF, GFR and cardiac output. Renal fraction of cardiac output (RBF/CO) showed a significant increase by 29.5% after the therapy, indicating that the renal vascular resistance decreased to a greater extent than the extrarenal vascular resistance. Standard renal clearance was performed in 10 inpatients whom 60 mg of dilitiazem was administered orally. Renal plasma flow (RPF) showed an average increase by 15% 3 hr after the administration of the drug, which was not, however, statistically significant. There was no certain trend for GFR and filtration fraction. Urinary sodium excretion (UNaV) began to increase one hr and reached its peak 2 hr after the medication in 9 out of the 10 patients. It may be concluded that diltiazem has a direct inhibitory action against the renal tubular reabsortion of sodium, although the participation of renal hemodynamics can not be denied.
盐酸地尔硫䓬是一种强效冠状动脉扩张剂,对18例患者进行了给药,以评估其对肾血流动力学和尿电解质排泄的影响。通过放射性同位素稀释体外计数法,对8例非卧床患者在用药前及用药后3或4周测定肾血流量(RBF)、肾小球滤过率(GFR)和心输出量。虽然治疗后RBF有增加趋势,但RBF、GFR和心输出量无统计学显著变化。心输出量的肾部分(RBF/CO)在治疗后显著增加29.5%,表明肾血管阻力比肾外血管阻力下降幅度更大。对10例口服60mg地尔硫䓬的住院患者进行了标准肾清除率测定。给药后3小时肾血浆流量(RPF)平均增加15%,然而无统计学显著性。GFR和滤过分数无特定趋势。10例患者中有9例尿钠排泄(UNaV)在用药后1小时开始增加,2小时达到峰值。可以得出结论,地尔硫䓬对肾小管钠重吸收有直接抑制作用,尽管不能否认肾血流动力学的参与。